CRISPR screens identify STUB1 as an inhibitor of cytokine signaling in CD8+ T cells

IF 27.6 1区医学 Q1 IMMUNOLOGY

Nature Immunology Pub Date : 2025-08-22 DOI:10.1038/s41590-025-02247-y

引用次数: 0

Abstract

Using in vivo CRISPR–Cas9 screens of CD8+ T cells in a melanoma model, we identified STUB1 as an inhibitor of T cell-mediated antitumor immunity. STUB1 forms a complex with CHIC2, and together, they negatively regulate the expression of cytokine receptors, thereby limiting intratumoral CD8+ T cell numbers and function.

Abstract Image

查看原文本刊更多论文

CRISPR筛选发现STUB1是CD8+ T细胞中细胞因子信号传导的抑制剂

在黑色素瘤模型中使用CD8+ T细胞的体内CRISPR-Cas9筛选，我们发现STUB1是T细胞介导的抗肿瘤免疫的抑制剂。STUB1与CHIC2形成复合物，它们共同负向调节细胞因子受体的表达，从而限制肿瘤内CD8+ T细胞的数量和功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Immunology 医学-免疫学

CiteScore

40.00

自引率

2.30%

发文量

248

审稿时长

4-8 weeks

期刊介绍： Nature Immunology is a monthly journal that publishes the highest quality research in all areas of immunology. The editorial decisions are made by a team of full-time professional editors. The journal prioritizes work that provides translational and/or fundamental insight into the workings of the immune system. It covers a wide range of topics including innate immunity and inflammation, development, immune receptors, signaling and apoptosis, antigen presentation, gene regulation and recombination, cellular and systemic immunity, vaccines, immune tolerance, autoimmunity, tumor immunology, and microbial immunopathology. In addition to publishing significant original research, Nature Immunology also includes comments, News and Views, research highlights, matters arising from readers, and reviews of the literature. The journal serves as a major conduit of top-quality information for the immunology community.